Valuation: Nexstim Plc

Market Cap 7.85Cr 9.09Cr 7.36Cr 6.71Cr 13Cr 869.28Cr 13Cr 86Cr 34Cr 435.51Cr 34Cr 33Cr 1.45TCr P/E 2026 *
69.4x
P/E 2027 * 36x
Enterprise Value 7.7Cr 8.92Cr 7.22Cr 6.58Cr 12Cr 852.66Cr 13Cr 85Cr 33Cr 427.18Cr 33Cr 33Cr 1.42TCr EV / Sales 2026 *
5.54x
EV / Sales 2027 * 4.68x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.09Cr
-0.05%-1.77%+20.82%+9.91% 22TCr
-0.41%-3.55%-3.38%-20.12% 14TCr
-0.92%-0.64%-18.78%+34.75% 14TCr
-0.04%+2.61%-49.76%+1.64% 7.51TCr
-0.93%-1.25%+16.07%+18.29% 5.28TCr
-0.79%-0.43%-17.43%-15.38% 5.07TCr
+0.19%+0.25%+26.19%+23.37% 4.19TCr
-1.06%-0.84%+41.09%+49.48% 4.05TCr
-2.02%-0.95%-1.26%+5.64% 3.33TCr
Average -0.65%+1.61%+1.51%+11.95% 8.82TCr
Weighted average by Cap. -0.53%+1.12%+0.48%+9.60%

Financials

2026 *2027 *
Net sales 1.39Cr 1.61Cr 1.3Cr 1.19Cr 2.23Cr 153.95Cr 2.26Cr 15Cr 5.99Cr 77Cr 6.04Cr 5.91Cr 256.56Cr 1.61Cr 1.86Cr 1.51Cr 1.38Cr 2.59Cr 178.31Cr 2.62Cr 18Cr 6.94Cr 89Cr 7Cr 6.85Cr 297.17Cr
Net income 11L 12.74L 10.32L 9L 17.67L 12Cr 17.92L 1.21Cr 47.41L 6.1Cr 47.84L 46.8L 20Cr 22L 25.48L 20.64L 18.8L 35.35L 24Cr 35.84L 2.42Cr 94.81L 12Cr 95.68L 93.6L 41Cr
Net Debt -15L -17.38L -14.07L -12.82L -24.1L -17Cr -24.43L -1.65Cr -64.64L -8.32Cr -65.23L -63.82L -28Cr -32L -37.07L -30.02L -27.34L -51.41L -35Cr -52.13L -3.52Cr -1.38Cr -18Cr -1.39Cr -1.36Cr -59Cr
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
40
Trader
Investor
Global
Quality
ESG MSCI
-